Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 18/20 | 1.00 |
| ▸ | SCD | O00767 | 7/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.53 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21535951 | 0.88 | SCD5 (0.87) | SCD5SCDCYP2C8CYP2B6CYP2C9 | |
| SCHEMBL21523672 | 0.86 | SCD5 (1.00) | SCD5SCDCYP2C8CYP2B6CYP2C9 | |
| SCHEMBL21523848 | 0.85 | SCD5 (1.00) | SCD5SCDCYP2C8CYP2B6CYP2C9 | |
| SCHEMBL21523617 | 0.84 | SCD5 (1.00) | SCD5SCDCYP2C8CYP2B6CYP2C9 | |
| SCHEMBL21523591 | 0.84 | SCD5 (1.00) | SCD5SCDCYP2C8CYP2B6CYP2C9 | |
| SCHEMBL21523622 | 0.83 | SCD5 (1.00) | SCD5SCDCYP2C8CYP2B6CYP2C9 | |
| SCHEMBL21523590 | 0.83 | SCD5 (1.00) | SCD5SCDCYP2C8CYP2B6CYP2C9 | |
| SCHEMBL21523801 | 0.83 | SCD5 (1.00) | SCD5SCDCYP2C8CYP2B6 | |
| SCHEMBL28535243 | 0.83 | SCD5 (0.71) | SCD5SCDCYP2C8CYP2B6CYP2C9 | |
| SCHEMBL21523745 | 0.83 | SCD5 (1.00) | SCD5SCDCYP2C8CYP2B6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112566636-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2021-03-26 | — | — | CN | disclosed |
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919885-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | SCD5 1575/4885SCD 2044/4885CYP2C8 2318/4885 |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | SCD5 1575/4885SCD 2044/4885CYP2C8 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.